Biotech Values

[semi_infinite]

AFMD +20% on Q1 update. Have to listen to CC to get details on LuminIce drop outs - kinda hilarious but also sad that patients/docs are trying to hide treatment/infections history to get into the trial. Only to be rejected after more thorough background review and slowing down the enrollment process for everyone involved (something to do with re-slotting once someone drops out for whatever reason). 2 of these patients are now trying Acetris first and when/if PD on Acetris if they want to re-enroll in trial. AFM28 mono getting 33% CR at highest P1 dose is also interesting since r/r AML patients have low NK cell counts.
IMO EV is low for the pipeline with AA probably in the cards for LuminIce, and now with nsclc egfrMut and r/r AML also.

https://www.affimed.com/affimed-reports-first-quarter-2024-financial-results-business-update/